ARDTHealthcare · Medical Care FacilitiesThe 13 Wall Street analysts covering Ardent Health, Inc. hold a median 12-month price target of $13 — +0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Ardent Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ARDT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | BMO Capital | Initiates | Market Perform | $11 |
| 18 Sept 2026 | Leerink Partners | Maintains | Outperform | $14 |
| 10 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 10 Aug 2026 | RBC Capital | Maintains | Outperform | $12 → $13 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $13 → $14 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 6 Aug 2026 | Truist Securities | Maintains | Buy | $12 → $13 |
| 6 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 14 July 2026 | Truist Securities | Maintains | Buy | $13 → $12 |
| 14 July 2026 | Truist Securities | Maintains | Buy | — |
| 9 July 2026 | RBC Capital | Maintains | Outperform | $13 → $12 |
| 9 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 May 2026 | UBS | Maintains | Buy | — |
| 10 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Mar 2026 | Leerink Partners | Maintains | Outperform | — |
| 20 Jan 2026 | JP Morgan | Maintains | Neutral | — |
| 18 Dec 2025 | Mizuho | Maintains | Outperform | — |
| 18 Dec 2025 | UBS | Maintains | Buy | — |
| 24 Nov 2025 | JP Morgan | Maintains | Neutral | — |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ARDT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Ardent Health, Inc. returned −10.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 31% of US stocks
Cheaper than 88% of US stocks
Cheaper than 56% of US stocks
Cheaper than 43% of US stocks
Higher than 25% of US stocks
Higher than 5% of US stocks
Higher than 51% of US stocks
Higher than 51% of US stocks
Higher than 50% of US stocks
Higher than 63% of US stocks
Higher than 66% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ardent Health, Inc. has a market value of $1.7B and an enterprise value of $3.6B.
Revenue in the twelve months to 30 June 2026: $6.4B. The latest quarter shrank 1.4% year on year.
Net income over the same four quarters: $168.6M, a 2.6% net margin.
Free cash flow in the twelve months to 30 June 2026: $304.8M.
Trailing P/E: 24.4×; forward P/E: 10.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ardent Health, Inc. employs 19,500 people — $329K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ardent Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ardent Health reported third-quarter earnings of $0.31 per share, above the Zacks Consensus Estimate of $0.24. Earnings were $0.52 per share in the year-ago quarter.
Why it matters — ARDT watchers may note the company exceeded the consensus earnings estimate, while reported earnings per share were lower than a year earlier.
Ardent Health announced results for the quarter ended September 30, 2026. The excerpt identifies this as the company’s third-quarter 2026 results release but provides no specific operating or financial figures.
Why it matters — ARDT watchers can note the results announcement, though the supplied excerpt does not include performance details.
Ardent Health appointed Gaurav Khanna as chief digital & information officer. He will lead the company’s technology, data, AI and digital strategy.
Why it matters — The appointment places leadership of Ardent’s technology and digital strategy with a new executive, an organizational development relevant to ARDT watchers.
Ardent Health announced it will release its third-quarter 2026 results after market close on Nov. 4, 2026. The company will host a conference call and webcast to review the results and hold a Q&A session on Nov. 5 at 10 a.m. ET.
Why it matters — ARDT watchers can note the scheduled dates for the company's quarterly results and management discussion.
Seeking Alpha reiterated a bullish view on Ardent Health, calling shares deeply undervalued despite recent profitability declines. Revenue continues to grow with management projecting $6.4–$6.7 billion for the year, while EBITDA and cash flow are expected to fall short of prior results. Professional fees pressured margins, but management expects this cost trend to moderate in the second half, signaling potential stabilization.
Why it matters — ARDT watchers would care because the piece highlights continued revenue growth and expectations of margin stabilization, even as profitability measures lag earlier results.
The 13 Wall Street analysts covering Ardent Health, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Ardent Health, Inc., 7 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Ardent Health, Inc. 70 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Ardent Health, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.1% from the last close, and Ticker Nerd's factor model ranks Ardent Health, Inc. 70 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ardent Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARDT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $14 over the next 12 months.
Ardent Health, Inc. returned -10.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Ardent Health, Inc. is a healthcare services company that owns and operates a network of hospitals, clinics, and other care facilities across the United States.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Ardent Health, Inc. (ARDT) Beats Q3 Earnings and Revenue Estimates". Ardent Health reported third-quarter earnings of $0.31 per share, above the Zacks Consensus Estimate of $0.24. Earnings were $0.52 per share in the year-ago quarter.
Ardent Health, Inc. is a healthcare services company that owns and operates a network of hospitals, clinics, and other care facilities across the United States. The company provides both general and specialty medical services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency care. Its operations span inpatient and ambulatory settings, supported by acute care hospitals, rehabilitation hospitals, surgical hospitals, ambulatory surgery centers, urgent care centers, free-standing emergency departments, diagnostic imaging centers, primary care clinics, specialty clinics, and telehealth services. Ardent Health, Inc. serves patients in growing mid-sized urban communities and works through a broad system of affiliated providers and subsidiaries to deliver integrated care across multiple settings. The company is based in Brentwood, Tennessee, and operates as a significant participant in the U.S. healthcare delivery market.
CEO Mr. David Caspers · 19,500 employees · United States · https://www.ardenthealth.com
